Kymab Group Limited, a leading human monoclonal antibody biopharmaceutical group, announces the appointment of Dr Sonia Quaratino as its first Chief Medical Officer. Dr Quaratino will manage the clinical development of the Group's expanding therapeutic antibody portfolio.
List view / Grid view
Filter the results
The monoclonal antibody biopharmaceutical group Kymab announced today that it has received a $9m grant from the Bill & Melinda Gates Foundation to accelerate the development of novel vaccines and therapeutics for infectious diseases, including HIV.
7 September 2015 | By Victoria White
The ranking recognises Kymab’s potential for rapid future sales growth and increasing international presence...
12 January 2015 | By Kymab
Combination of Kymab’s unique antibody platform and cytokine technologies expected to deliver enhanced efficacy and tolerability...
16 December 2014 | By Kymab
Kymab, a monoclonal antibody biopharmaceutical company, founded on research from the Wellcome Trust Sanger Institute announces that it has been awarded a grant from the Wellcome Trust to lead a consortium developing new treatments in the fight against Ebola...